Meningococcal group W-135 polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup W-135. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and... It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.
- First approval
- Canada, 2000 · United States, 1981 · European Union, 2020
- Also known as
- Meningococcal polysaccharide antigen group W-135 · neisseria meningitidis group W-135 capsular polysaccharide antigen · Neisseria meningitidis group W-135 polysaccharide antigen, A
- Brand names
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Meningococcal polysaccharide vaccine group W-135, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account